VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Vir Biotechnology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$10.21+0.25 (+2.51%)
Close on Oct 19, 2026
- Market cap
- $1.72B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Gross margin
100.0%−0.0 pts over 5 years
Operating margin
-699.2%−310.3 pts over 5 years
Net margin
-638.9%−247.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -7.6% | -65.1% | -2.1% | – | |
| Gross profit | -6.6% | -64.0% | -2.1% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -52.4% | -45.7% | |
| Return on assets | – | -41.7% | -36.5% | |
| Current ratio | – | 7.80 | 5.54 | |
| Capex to revenue | – | 8.6% | 7.0% | |
| Diluted shares | – | 119M | 139M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Vir Biotechnology generated $3.33B from operations and spent $123.53M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$3.33B
Used
$123.53M
Capital expenditure$123.53M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-638.9%
×Asset turnover0.06×
×Equity multiplier1.25×
=Return on equity, FY2025-45.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -638.9% | 0.06× | 1.25× | -45.7% |
| FY2024 | -703.4% | 0.04× | 1.21× | -38.1% |
| FY2023 | -713.7% | 0.04× | 1.29× | -33.5% |
| FY2022 | 31.9% | 0.68× | 1.36× | 29.4% |
| FY2021 | 48.3% | 0.76× | 1.34× | 49.2% |
| FY2020 | -391.1% | 0.11× | 1.25× | -52.4% |
| FY2019 | -2159.0% | 0.02× | 2.87× | -142.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$437.99M
- Cash generatingOperating cash flow above zero-$391.78M
- Return on assets improvedROA up on the prior year-27.2% → -31.3%
- Earnings backed by cashOperating cash flow above net income-$391.78M vs -$437.99M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose8.71 → 5.54
- No dilutionShare count did not rise136M → 139M
- Gross margin improvedGross margin up on the prior year98.86% → 99.96%
- More efficientAsset turnover rose0.04 → 0.05